TSO3 — Investor Presentation (September 2017)
30 slides from TSO3's investor presentation, September 2017
Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing
To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Corporate Presentation | September 2017 1
Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures
Important Cautions Regarding Forward Looking Statements and Other Disclosures The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve certain risks
Slide 3: Vision and Purpose: A Sterile Device for Every Procedure
VISION. PURPOSE. To Create and Deliver The New Standard of Care In Sterile Reprocessing™ A Sterile Device for Every Procedure 3
Slide 4: Major Milestones Laying Foundation for Growth
Major Milestones Laying Foundation for Growth 1998 - 2008 2009-2014 2015 2016 2017 • Founded • Product redesign • Exclusive distribution • Shipped 110 STERIZONE® • TTM Revenue of agreement with Getinge VP4 Sterilizers to Getinge $16.1M1 • HQ: Québec City, • Introduced - $7.5M in cash + Canada STERIZ
Slide 5: STERIZONE VP4 Sterilizer
STERIZONE ® VP4 Sterilizer Advantages Dynamic Sterilant Delivery • Single cycle – easy, error-free cycle selection System™ • Mixed load sterilization Proprietary Technology automatically adjusts the sterilant quantity based on load • Up to 75 Ib in a single load composition, weight and temperature.
Slide 6: Protected Breakthrough Technologies
Protected Breakthrough Technologies /// 138 Patents + 47 Patents Pending Worldwide 1. Insert Room Temperature Instruments Into a Warm Chamber 2. Create a Vacuum and Inject Small Amounts of Vapourized Heated Sterilant Over Time 3. Micro Condensation Forms on the Instruments Dynamic Sterilant Delivery
Slide 7: A Sterile Device for Every Procedure
PURPOSE A Sterile Device for Every Procedure 7
Slide 8: Global Market Opportunity
Global Market Opportunity United States • ~ 10,000 Hospitals and Ambulatory Surgery Centers1 • ~ 48 million annual procedures1 • ~ 15 million colonoscopies performed annually2 • > 500,000 endoscopic retrograde cholangiopancreatographies performed annually3 Canada • ~ 1,400 Hospitals4 • ~ 2.4 million
Slide 9: Aging Population – Driving Growth in MIS
Aging Population – Driving Growth in MIS Driving Growth in MI Surgeries and Endoscopies Growth in U.S. Population Age Groups 65+1 Over 90,000,000 65 Years 80,000,000 70,000,000 Old 60,000,000 50,000,000 40,000,000 88% of ophthalmology surgeries 30,000,000 20,000,000 70% of cardiothoracic surgeries 1
Slide 10: Increasing Demand for MIS and Endoscopy Procedures
Increasing Demand for MIS and Endoscopy Procedures Minimally Invasive Aging population expected to Surgery (MIS) result in increasing demand for minimally invasive diagnostic and surgical procedures (MIS) • Effective • Faster Recovery and associated devices • More profitable Patients age 65+ current
Slide 11: Health Care Procedures
Health Care Procedures Surgical – OR Support • $6b+ Sterilization Existing Market1 • High Growth Low Temperature Component Millions of Surgical and Diagnostic Procedures Each Year Diagnostic – GI • 50m+ Procedures/year2 • No sterilization for most 1) Market and Market, June 2016 2 )Becker’s GI & End
Slide 12: OR Market: Sterile Devices
OR Market: Sterile Cost Effectiveness Devices Convenience/Simplicity Throughput TSX:TOS 12
Slide 13: A Better Solution
A Better Solution Old Technology TSO3 Technology • 20+ year-old core • Next generation industry technology technology • Single sterilant • Dual Sterilant • Fixed delivery • Dynamic Delivery • Small loads • Simple Single Cycle Operation • Segregated loads • Large Loads Sterrad® NX Sterrad ® 100NX • E
Slide 14: Larger, Mixed Loads
Larger, Mixed Loads Competition VS STERIZONE® VP4 Sterilizer TSX:TOS 14
Slide 15: Diagnostic GI/Endoscopic Market Driver
Diagnostic GI/Endoscopic Market Driver A Shift to a New Standard of Care: Patient Safety TSX:TOS 15
Slide 16: Not Sterile – Why? Spaulding Classification
Not Sterile – Why? Spaulding Classification TSX:TOS 16
Slide 17: A New Problem: Endoscopes and Superbugs
A New Problem: Endoscopes and Superbugs “Deaths from Drug-Resistant Infections Set to Skyrocket” Deaths from antimicrobial resistant infections and other causes in 20501 Two million+ Americans suffer Carbapenem-resistant CRE infections are linked to Inadequately-cleaned endoscopes annually from anti
Slide 18: How Change Happens
How Change Happens Patient and Medical Technology Facility Demand Advancement • Patient Safety • STERIZONE® VP4 Sterilizer • Litigation • Cost Reduction Market Change Regulatory Change • FDA Regulation Advancement • Industry Dialogue and Guidelines TSX:TOS 18
Slide 19: Public Awareness
Public Awareness Nation World Los Angeles Times HealthLeaders Media “FDA links ‘superbug‘ to key medical device.” “Jury orders Olympus to pay $6.6 million “Infection fears prompt Fujifilm but rejects claims its medical scopes are Medical Systems Duodenoscopes “LOS ANGELES — A ‘superbug‘ outbreak uns
Slide 20: Industry Call-to-Action
Industry Call-to-Action “Despite reprocessing in accordance with US “…Despite adherence to strict “We have to transition to sterilization. That guidelines, viable microbes and biologic debris guidelines…bacteria can at times remain on is the only way we’ll eliminate the persisted in clinically used
Slide 21: Modernizing GI Endoscope Reprocessing
Modernizing GI Endoscope Reprocessing Old TSO3 STERIZONE® VP4 Sterilizer TSX:TOS 21
Slide 22: Shift is Happening
Shift is Happening Dirty Endoscopes Raising A 21st Century Nosocomial Deadly Bacteria On Seattle Hospital Sues Alarms for Colonoscopies Issue With Endoscopes Medical Scopes Trigger Olympus Over Superbug Infections Outbreak 2009 2013 2014 2014 2015 2015 2015 2015 2015 VA Officials Get Probed For Dirt
Slide 23: Shift is Happening
Shift is Happening Cross-contamination More Infections Dirty Endoscopes An Epidemic Is On Hospitals Failing to Not Limited to From Contaminated Top ECRI Institute's the Rise That May Report Outbreaks Duodenoscopes Scopes Suspected in 2016 Technology Kill More People Due to Contaminated L.A. Hazards
Slide 24: Shift is Happening
Shift is Happening Why It Took Years For The Superbug Infections Must Redesigned Olympus Carbapenem-Resistant FDA to Warn About Be Listed On Death Scopes linked to Superbug Enterobacteriaceae in Patients From Infections Tied to Medical Certificate Under Proposed Outbreak: 7 Things to the US Veterans
Slide 25: Industry First: FDA Clearance of TSO Endoscope Claims
Industry First: FDA Clearance of TSO Endoscope Claims 3 CLEARED Video Colonoscope The only FDA cleared device validated to sterilize colonoscopes, gastroscopes and other flexible endoscopes up to 3.5m in length and with four or fewer channels. Video Gastroscope TSX:TOS TSX:TOS 25
Slide 26: Duodenoscopes – the point on the spear
Duodenoscopes – the point on the spear Duodenoscope Expanded Claims: FDA – Duodenoscopes • Already cleared in Canada & Europe • Launched US regulatory filings for duodenoscopes; goal: US clearance by end of 2017 Market Launch and Awareness • Duodenoscopes now being terminally sterilized in Western C
Slide 27: Commercialization
Commercialization Joacim Lindoff President of Surgical Workflows Getinge Group • Getinge Group - Exclusive Global Distributor • Global sales and service; 3,000+ associates in 36 countries • Paid $7.5 million up-front license fee • Minimum annual purchase commitments “The STERIZONE® VP4 Sterilizer un
Slide 28: Summary
Next Generation Technology Extensive Patent Portfolio Razor/Razorblade Business Model FDA-cleared Device for Terminal Sterilization of Colonoscopes SUMMARY and other flexible endoscopes Global Distribution Partner Growing Sales Financially Sound TSX:TOS 28
Slide 29: Key Stats (TSX: TOS)
Key Stats (TSX: TOS) /// All Dollars in USD, Unless Noted Otherwise Stock Price (9/7/17) CAD$2.52 Quarterly Revenue Growth 52 Week High-Low CAD$3.73-$2.05 US$ Millions $4.6 Shares Outstanding (mrq) (no warrants) 92.7M $4.2 Average Daily Volume (90 day) 220,269 $3.7 Market Capitalization CAD$233M $3.
Slide 30: T Sh,
T Sh,